These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20233418)

  • 21. Biomarkers in early-phase trials: fundamental issues.
    Yee LM; Lively TG; McShane LM
    Bioanalysis; 2018 Jun; 10(12):933-944. PubMed ID: 29923753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The failure of anxiolytic therapies in early clinical trials: what needs to be done.
    Stewart AM; Nguyen M; Poudel MK; Warnick JE; Echevarria DJ; Beaton EA; Song C; Kalueff AV
    Expert Opin Investig Drugs; 2015 Apr; 24(4):543-56. PubMed ID: 25727478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for a non-inferiority clinical trial design focused on subpopulations.
    Kulkarni PM; Meadows ES; Ahuja S; Muram D; Plouffe L
    Curr Med Res Opin; 2004 Oct; 20(10):1641-7. PubMed ID: 15462697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cancer and leukemia group B pathology committee at 50.
    Compton C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3617s-21s. PubMed ID: 16740795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
    Khin NA; Kronstein PD; Yang P; Ishida E; Hung HM; Mathis MV; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating real-life high-throughput screening data.
    Gribbon P; Lyons R; Laflin P; Bradley J; Chambers C; Williams BS; Keighley W; Sewing A
    J Biomol Screen; 2005 Mar; 10(2):99-107. PubMed ID: 15799953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of preclinical irreproducibility on drug development.
    Freedman LP; Gibson MC
    Clin Pharmacol Ther; 2015 Jan; 97(1):16-8. PubMed ID: 25670378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric cardiovascular safety: challenges in drug and device development and clinical application.
    Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW
    Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.
    Dmitrienko A; Paux G; Pulkstenis E; Zhang J
    J Biopharm Stat; 2016; 26(1):120-40. PubMed ID: 26391238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical attrition due to biased preclinical assessments of potential efficacy.
    Lindner MD
    Pharmacol Ther; 2007 Jul; 115(1):148-75. PubMed ID: 17574680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Building data quality into clinical trials.
    Crerand WJ; Lamb J; Rulon V; Karal B; Mardekian J
    J AHIMA; 2002; 73(10):44-6, 48-53, 2; quiz 55-6. PubMed ID: 12432815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.